The intestine is essential for the modulation of nutrient absorption and the removal of waste. Gut pathologies, such as cancer, inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), and celiac disease, which extensively impact gut functions, are thus critical for human health. Targeted drug delivery is essential to tackle these diseases, improve therapy efficacy, and minimize side effects. Recent strategies have taken advantage of both active and passive nanocarriers, which are designed to protect the drug until it reaches the correct delivery site and to modulate drug release via the use of different physical–chemical strategies. In this systematic review, we present a literature overview of the different nanocarriers used for drug delivery in a set of chronic intestinal pathologies, highlighting the rationale behind the controlled release of intestinal therapies. The overall aim is to provide the reader with useful information on the current approaches for gut targeting in novel therapeutic strategies.

The thymus plays a pivotal role in the generation of immunocompetent T cells. Although its function is dependent on its complex extracellular matrix, its 3D architecture and mechanical properties remain poorly characterised This knowledge gap limits efforts to model and engineer the organ, which is a critical step towards the development of strategies for the treatment of many haematological and autoimmune diseases. Here, we provide the first comprehensive multiscale dataset of bovine thymic extracellular matrix architecture and viscoelastic behaviour, including quantitiative descriptors such as relaxation times, instantaneous and equilibrium elastic moduli, storage and loss moduli, and spatial mechanical heterogeneity. Taken together, our data define the thymus as a compliant, highly dissipative viscoelastic organ with a fibrillar architecture. They also represent a unique database, which, for the first time, paves the way for quantitative thymus tissue engineering.